This study provides a national overview of visual field testing and antiglaucoma drug prescribing trends by optometrists in Australia using comprehensive Medicare data from 2003 to 2022. The inclusion of antiglaucoma drugs in the optometric Pharmaceutical Benefits Scheme coincided with a marked rise in visual field testing and prescribing activity by optometrists.